X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WYETH LTD VENUS REMEDIES/
WYETH LTD
 
P/E (TTM) x -677.5 27.7 - View Chart
P/BV x 0.2 5.3 3.7% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 VENUS REMEDIES   WYETH LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
WYETH LTD
Mar-13
VENUS REMEDIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs2181,044 20.9%   
Low Rs82818 10.0%   
Sales per share (Unadj.) Rs365.6298.6 122.5%  
Earnings per share (Unadj.) Rs1.557.2 2.6%  
Cash flow per share (Unadj.) Rs37.958.4 64.9%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs382.5249.5 153.3%  
Shares outstanding (eoy) m11.4422.72 50.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.1 13.2%   
Avg P/E ratio x101.016.3 620.7%  
P/CF ratio (eoy) x4.015.9 24.8%  
Price / Book Value ratio x0.43.7 10.5%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m1,71721,157 8.1%   
No. of employees `0001.00.5 207.3%   
Total wages/salary Rs m324400 81.1%   
Avg. sales/employee Rs Th4,100.713,787.4 29.7%   
Avg. wages/employee Rs Th318.0813.0 39.1%   
Avg. net profit/employee Rs Th16.72,643.3 0.6%   
INCOME DATA
Net Sales Rs m4,1836,783 61.7%  
Other income Rs m20353 5.7%   
Total revenues Rs m4,2037,136 58.9%   
Gross profit Rs m8121,617 50.2%  
Depreciation Rs m41727 1,566.9%   
Interest Rs m3806 6,905.5%   
Profit before tax Rs m351,938 1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m18632 2.9%   
Profit after tax Rs m171,301 1.3%  
Gross profit margin %19.423.8 81.4%  
Effective tax rate %51.632.6 158.1%   
Net profit margin %0.419.2 2.1%  
BALANCE SHEET DATA
Current assets Rs m2,7716,984 39.7%   
Current liabilities Rs m1,9312,056 93.9%   
Net working cap to sales %20.172.6 27.6%  
Current ratio x1.43.4 42.2%  
Inventory Days Days12599 126.0%  
Debtors Days Days5424 224.5%  
Net fixed assets Rs m5,328244 2,181.1%   
Share capital Rs m114227 50.4%   
"Free" reserves Rs m4,1775,441 76.8%   
Net worth Rs m4,3765,668 77.2%   
Long term debt Rs m1,91125 7,642.0%   
Total assets Rs m8,4287,901 106.7%  
Interest coverage x1.1353.3 0.3%   
Debt to equity ratio x0.40 9,897.7%  
Sales to assets ratio x0.50.9 57.8%   
Return on assets %4.716.5 28.5%  
Return on equity %0.422.9 1.7%  
Return on capital %6.634.0 19.4%  
Exports to sales %00.2 0.0%   
Imports to sales %20.536.3 56.5%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs m8582,465 34.8%   
Fx inflow Rs m015 0.0%   
Fx outflow Rs m8582,677 32.1%   
Net fx Rs m-858-2,662 32.2%   
CASH FLOW
From Operations Rs m469923 50.8%  
From Investments Rs m29317 9.2%  
From Financial Activity Rs m-464-481 96.4%  
Net Cashflow Rs m35759 4.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 7.2 8.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 30.4 218.4%  
Shareholders   20,121 21,978 91.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - SUVEN LIFE COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS